VX-708
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
May 15, 2023
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=100 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed
Trial completion • Pain
April 20, 2023
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=100 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting
Enrollment closed • Pain
March 30, 2023
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=64 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed
Trial completion • Pain
October 12, 2022
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=54 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting
Enrollment open • Pain
August 29, 2022
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=54 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Pain
April 26, 2022
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=110 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Pain
1 to 6
Of
6
Go to page
1